Business Context and Reporting Period
Immatics N.V. filed this Form 6-K on October 20, 2025, to disclose updated clinical data from its ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in patients with metastatic uveal melanoma. The data cutoff date was September 24, 2025.
Key Clinical Metrics
The filing focuses on clinical efficacy and safety rather than financial performance. No revenue, profit, cash flow, or debt metrics are provided in this document.
- Patient Cohort: 16 patients with metastatic uveal melanoma received a one-time infusion at the recommended Phase 2 dose (median ~4 billion TCR T cells).
- Confirmed Objective Response Rate (cORR): 67% (10/15 evaluable patients).
- Disease Control Rate (DCR): 88% (14/16 patients).
- Median Duration of Response (mDOR): 11 months (range 4.4 to 31.6 months).
- Median Progression-Free Survival (mPFS): 8.5 months (69% rate at 6 months; 39% at 12 months).
- Median Overall Survival (mOS): Not reached (71% rate at 12 months).
- Liver Metastasis Activity: 14/16 patients had liver lesions with a median shrinkage of 49.6%.
Material Changes and Prior Comparisons
This filing represents an update to previously reported data from the Phase 1b dose expansion. A notable finding is the efficacy in patients with prior TCR-based therapy exposure: 11 of 16 patients had received prior TCR bispecifics, with six achieving a confirmed partial response, one a partial response, and three stable disease.
Safety Profile
- Adverse Events: Most frequent events were anticipated cytopenias from lymphodepletion.
- Cytokine Release Syndrome (CRS): Mostly Grade 1 (37.5%) or Grade 2 (43.8%); 18.8% Grade 3; 0% Grade 4. No long-term CRS observed; most resolved by day 14.
- Severe Events: No anzu-cel-related Grade 5 events were observed.
Guidance, Outlook, and Development Path
Based on the promising data, Immatics has initiated a Phase 2 cohort targeting approximately 30 uveal melanoma patients at select centers in the United States and Germany. Prospective PRAME testing is no longer required for inclusion due to the high prevalence of PRAME expression in uveal melanoma. Management views the consistent tolerability and activity across uveal and cutaneous melanoma as a strong rationale for a parallel late-stage development strategy.
Investor Verification Checklist
- Verify the specific enrollment criteria and patient demographics for the newly initiated Phase 2 cohort.
- Confirm the timeline for the Phase 2 data readout and potential regulatory filing dates.
- Review the full safety data regarding long-term adverse events beyond the current follow-up period.
- Assess the financial impact of expanding clinical operations to the United States and Germany.
- Check for any updates on the company's cash runway and capital requirements to support the Phase 2 expansion.